BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Human chorionic gonadotropin
,
Clofibrate
,
rs7903146
,
TGFB1
,
cell-cell adhesion
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
2,4,5-T
Summary
General Info
Curated Studies
Most Correlated Studies
There were no matches for 2,4,5-T
Explore Curated Studies Results
Literature
Most Relevant Literature
A mechanistic study of the photodegradation of herbicide 2,4,5-trichlorophenoxyacetic acid in aqueou…
Degradation of 2,4-dichlorophenoxyacetic acid (2,4-D) and 2,4,5-trichlorophenoxyacetic acid (2,4,5-T…
Characterization of 2,4-dichlorophenoxyacetic acid and 2,4,5-trichlorophenoxyacetic acid-degrading f…
Degradation of 2,4,5-trichlorophenoxyacetic acid by a novel Electro-Fe(II)/Oxone process using iron …
TCDD exposure estimation for workers at a New Zealand 2,4,5-T manufacturing facility based on serum …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study
Chimeric Antigen Receptor T-Cell (CAR-T) Cells in Patients With R/R T-LBL
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T…
Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma
Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infa…
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ